Study to assess the tolerability and durable effect of AMG 145 in patients with Hyperlipidemia

Registry ID

EUCTR2011-003827-37

Source registry

EUCTR

Status

Completed

Phase

PHASE3

Sponsor

Amgen Inc

Start date

2012-01-06

Completion date

2013-10-14

Last update

2026-08-16

Conditions

• Hyperlipidemia

Summary

To evaluate the effect of 52 weeks of subcutaneous (SC) AMG 145 monthly (QM), compared with placebo, on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) when added to background lipid-lowering therapy

Locations

• , , Czechia
• , , Austria
• , , Denmark
• , , Belgium
• , , Hungary

Related clinical trials

• Bacillus Subtilis and Enterococcus Faecium Probiotic Plus Lipid-Lowering Therapy for Hypertriglyceridemic Acute Pancreatitis: A Prospective RCT
• Ursodeoxycholic Acid Attenuates Statin-Induced Impaired Glucose Tolerance
• Assessment of the Effects and Safety of Spermidine Supplementation on Blood Lipids and Body Weight in Overweight or Obese Individuals With Hyperlipidemia
• Regional Innovation in Chronic Disease and Elderly Care
• A Trial to Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemia
• New Taipei City 888 Digital Medical AI Platform for Prevention and Care of the Three Highs and Cardio-Renal-Vascular Diseases

View on source registry